MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndrome.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 27122614.
- Also identified by DOI 10.1126/scitranslmed.aad9370 and PMC identifier 4995450.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fragile X syndrome, the most common form of inherited intellectual disability, is caused by loss of the fragile X mental retardation protein (FMRP). However, the mechanism remains unclear, and effective treatment is lacking. We show that loss of FMRP leads to activation of adult mouse neural stem cells (NSCs) and a subsequent reduction in the production of neurons. We identified the ubiquitin ligase mouse double minute 2 homolog (MDM2) as a target of FMRP. FMRP regulates Mdm2 mRNA stability, and loss of FMRP resulted in elevated MDM2 mRNA and protein. Further, we found that increased MDM2 expression led to reduced P53 expression in adult mouse NSCs, leading to alterations in NSC proliferation and differentiation. Treatment with Nutlin-3, a small molecule undergoing clinical trials for treating cancer, specifically inhibited the interaction of MDM2 with P53, and rescued neurogenic and cognitive deficits in FMRP-deficient mice. Our data reveal a potential regulatory role for FMRP in the balance between adult NSC activation and quiescence, and identify a potential new treatment for fragile X syndrome.
Medical subject headings
- Adult Stem Cells
- Fragile X Messenger Ribonucleoprotein 1
- Fragile X Syndrome
- Neural Stem Cells
- Proto-Oncogene Proteins c-mdm2